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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not 
temozolomide in combination with interferon alpha-2b a safe and effective treatment for 
malignant melanoma. 
Study Design: Review of three randomized controlled trials published in the United States and 
Britain between 2003 and 2005. 
Data Sources: Three non-blind randomized controlled trials were found via Cochrane library 
and PubMed. 
Outcomes Measured: Efficacy was measured by survival greater than or equal to 12 months, 
with one (experimental) group receiving treatment with oral temozolomide (TMZ) and 
subcutaneous interferon alpha-2b (IFN-∝2b) and the other (control) group receiving oral TMZ 
alone. Safety was measured by rates of nausea with the same experimental and control groups. 
Safety was also measured by adverse event rates, with one group receiving combination 
treatment with IFN-∝2b in a body surface area-based (BSA) dose, and the other group receiving 
combination treatment with IFN-∝2b in a fixed dose. 
Results: Kaufman et al and Danson et al demonstrated increased survival at 12 months when 
comparing treatment with TMZ + IFN-∝ to TMZ monotherapy (ABI 9.7% and 8%, 
respectively). Danson et al also found increased rates of nausea with combination treatment 
compared to TMZ alone (ARI 11%, NNH 10). Ritchtig et al showed a slightly increased rate of 
adverse events with an increased dose of IFN-∝2b when combined with TMZ (ARI 1.1%, NNH 
90). No statistical analyses were performed on the data. 
Conclusions: Based on these results, it is inconclusive if TMZ + IFN-∝2b is a safe and effective 
treatment for malignant melanoma. Although results on survival suggest a benefit to combination 
treatment, statistical analysis is required. Results for safety demonstrated increased adverse event 
and nausea rates both with the addition of IFN-∝2b and at increased doses of IFN-∝2b, however 
small sample size and lack of statistical analysis make it difficult to assume the safety of 
combination treatment. 
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INTRODUCTION 
Malignant melanoma is an aggressive cancer of melanocytes, the pigment-producing 
cells of the skin.1 This paper evaluates three randomized, controlled trials (RCTs) comparing the 
safety and efficacy of temozolomide (TMZ) in combination with interferon alpha-2b (IFN-∝2b) 
in the treatment of malignant melanoma.  
Melanoma is the leading cause of death due to skin disease, accounting for more than 
8,000 deaths per year.2 The incidence of melanoma in the United States is increasing. The risk of 
developing the disease for a Caucasian man born in 2010 is 1 in 39, and 1 in 58 for a Caucasian 
woman.3 This is compared to a 1 in 500 chance for an individual born in 1935.3 In addition to the 
lives lost to this aggressive skin disease, its toll can be measured in the financial burden it 
carries. An individual who dies from melanoma loses an average of $413,000 in future earnings, 
which translates to a total loss of $3.5 billion in earnings per year due to melanoma death.2 
Additionally, an American loses 20.4 years of potential life due to a death from melanoma, 
compared to an average of 16.6 years from other malignancies.2 This loss of potential life 
highlights the great need to improve the treatment of this disease.  
In 2012 there were an estimated 76,250 cases of melanoma, accounting for 4% of cancers 
in men and 3% in women.4 Both the commonness and the lethality of the disease highlight the 
importance to recognize and act upon its earliest signs. A pigmented lesion that is suspicious for 
malignant melanoma often have one or more of the “ABCDE” characteristics, which include 
asymmetry, irregular border, variegated color, diameter > 6 mm, and evolution. Identified risk 
factors include freckles, fair complexion, red or blond hair, blue eyes, family history of 
melanoma, the presence of multiple nevi, and those whose first sunburn occurred at an early 
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age.4 The single most important prognostic factor for a melanoma is the depth of skin that it 
penetrates. Ten year survival rate for a tumor that is < 1 mm thick is 95%, compared to 30% for 
tumors that penetrate > 4 mm.4 Metastatic melanoma carries a 10% survival rate and has 
historically been resistant to chemotherapy.4 
Melanoma is usually treated by local excision, with the addition of sentinel lymph node 
biopsy for tumors > 1 mm deep or with high risk histologic features.4 For regional recurrences in 
extremities, isolated limb perfusion or melphalan and hyperthermia are used.3 Dacarbazine is 
considered standard systemic chemotherapy and is associated with a 15% response rate.4,5 High 
dose IFN-∝2b is also utilized but is associated with high toxicity.4 
TMZ is an oral compound which shares an active breakdown product with dacarbazine.5 
TMZ advantages over dacarbazine include better absorption when taken orally, and better 
penetration in all tissues of the body since it does not require enzymatic activation in the liver.5 
TMZ also has demonstrated better response in treating brain metastases due to its ability to 
penetrate the blood-brain barrier.5 This is an important feature due to the propensity for 
melanoma to metastasize to the brain. IFN-∝2b has been used in combination with dacarbazine 
in the past and has shown improved tumor response rates but has not shown an increase in 
survival.4  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not temozolomide 
in combination with interferon alpha-2b is a safe and effective treatment for malignant 
melanoma. 
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METHODS 
Adult men and women between the ages of 18 and 88 with malignant melanoma were 
included in all three studies. Interventions studied were the use of TMZ in combination with 
INF-∝2b. Comparisons were made between TMZ alone and TMZ in combination with IFN-∝2b 
in a fixed (rather than BSA-based) dose. Outcomes measured were survival greater than or equal 
to one year, rates of nausea, and adverse drug event rates. All three studies were randomized, 
controlled trials.  
All articles were published in peer-reviewed journals and were originally published in 
English. Articles were researched via Cochrane library and PubMed using key words 
“temozolomide interferon alpha melanoma”. Articles were selected based on relevance to my 
clinical question and if they reported patient-oriented outcomes. Inclusion criteria were if studies 
were randomized, controlled trials published between 1999 and the present. Exclusion criteria 
were if patients were under 18 years of age. Statistics reported include RRI, ARI, NNH, RBI, 
ABI, and NNT. Table 1 describes the demographics and characteristics of each study. 
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Table 1. Demographics & characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Danson et 
al5 (2003) 
RCT 181 18-
88 
- Advanced metastatic 
melanoma 
- No previous chemotherapy 
- Full recovery from 
previous therapy 
- Adequate bone marrow 
reserve (neutrophils > 
1,500/µL; platelets > 
100,000 µ/L, Hgb > 10g/dL) 
- Urea and creatinine < 1.5 x 
the upper limits of 
laboratory normal (ULN) 
- Adequate hepatic function 
(total bilirubin < 1.5 x ULN, 
AST < 3 x ULN, alkaline 
phosphatase < x ULN 
- Adequate birth control 
measures 
 
- Pregnant or nursing 
- Uncontrolled 
vomiting that would 
interfere with 
administration of oral 
medication 
- biological therapy 
within 4 weeks of 
administration of 
temozolomide 
- If known HIV + 
- Clinically 
significant 
comorbidity that 
would interfere with 
study evaluations 
 
4 Experimental: oral 
temozolomide 200 
mg/m2 PO qd x 5d 
with IFN-∝2b 5 
mIU SQ every 
MWF; Treatment 
cycles repeated 
every 28 days  
VS Control: 
temozolomide PO 
200 mg/m2 at 8-
hour intervals for 
a total of five 
doses, repeated 
every 28 days  
 
 
Kaufman et 
al6 (2005) 
RCT 294 18-
75 
- Melanoma stage IV with 
no prior systemic therapy in 
stage IV 
- Karnofsky performance 
status > 60%  
- WBCs > 3,000/mm2, 
platelets >100,000, serum 
creatinine < 2x ULN, 
bilirubin < 1.5 mg/dL 
- Prior treatment (adjuvant, 
stage III) had to be 
completed at least 4 weeks 
before study 
 
- Evidence of CNS 
metastases 
- Major concomitant 
illness of 
cardiovascular, 
respiratory, or renal 
system 
- Pregnant or nursing 
- Primary ocular or 
mucosal melanoma 
- Nonmeasurable 
disease 
 
23 Experimental: oral 
temozolomide 200 
mg/m2/day, days 
1-5 every 28 days, 
in combination 
with subcutaneous 
IFN-∝2b 5 
mU/m2; days 1, 3, 
and 5 every week 
VS Control: 
Oral 
temozolomide 
(same dose) alone 
Ritchtig et 
al7 (2004) 
RCT 47 37-
74 
- Stage IV metastatic 
melanoma that is surgically 
incurable 
- Eastern Cooperative 
Oncology Group 
performance status of 0-2 
- Adequate organ function: 
Hgb > 10g/dL, serum 
creatinine < 1.5 x upper 
limit of normal range 
(ULN), leukocytes > 3,000 
g/L, platelets > 100,000 g/L, 
liver function < 3 x ULN, 
alkaline phosphatase < 3 x 
ULN, bilirubin < 2 x ULN 
- Life expectancy > 12 
weeks 
 
Not indicated 0 Experimental: 
temozolomide 150 
mg/m2 days 1-5 
PO every 28 days 
with IFN-∝2b 10 
MIU/m2 every 
other day 
VS 
Control: 
temozolomide 150 
mg/m2 on days 1-
5 every 28 days 
with IFN-α2b in a 
fixed dose of 10 
mIU every other 
day 
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OUTCOMES MEASURED 
All outcomes measured were patient-oriented evidence that matters (POEMs). Danson et 
al and Kaufman et al measured survival greater than or equal to 12 months.5,6 The amount of 
people in each group still living after 12 months were counted and reported as a percentage. 
Adverse events were also studied. Ritchtig et al measured adverse drug events, including 
neurological symptoms, drug-induced skin eruption, sepsis, and brain hemorrhage.7 Patients 
reported any adverse events that they experienced during the course of treatment, and adverse 
events were differentiated from common side effects such as nausea, vomiting, arthalgia, 
myalgia, and headache. Danson et al measured the most common side effect of nausea.5 Patients 
who reported nausea during the course of treatment were recorded and counted as a percentage 
of the total population studied.  
RESULTS 
Three randomized controlled trials that reported dichotomous data were used in this 
review. Two trials studied the combination of TMZ with IFN-∝2b compared to the use of TMZ 
alone.5,6 One study analyzed the use of TMZ with IFN-∝2b in a BSA-based dose compared to 
fixed dosing.7 Dosages of TMZ varied from 150 mg/m2 to 200 mg/m2, and it was given once 
daily orally for five days once per 28-day cycle. TMZ dose frequency differed in the control 
group of Danson et al in which it was given every 8 hours for a total of 5 doses for every 28-day 
cycle.5 Dosages of IFN-∝2b ranged from 5 milliunits/m2 (mU/ m2) subcutaneously on days one, 
three, and five to 10 million international units (mIU) subcutaneously on days one, three and 
five. All three studies utilized 28-day treatment cycles. 
Vincento, Temozolomide, Interferon-∝2b and Melanoma 6 
All studies required patients to have stage IV melanoma, however Kaufman et al 
excluded patients who had metastases to the central nervous system.6 Both Kaufman et al and 
Danson et al indicated that their patients must not have received previous chemotherapy for their 
disease in Stage IV, however Ritchtig et al did not make this specification.5,6,7 The study by 
Kaufman et al was performed in an outpatient setting, while Ritchtig et al and Danson et al did 
not specify whether their studies were performed on an outpatient or inpatient basis.5,6,7 The 
number of patients that withdrew from each study is indicated in Table 1.  
In the study by Kaufman et al, the intent to treat population was made up of 280 patients, 
139 in the TMZ arm, and 143 in the TMZ + IFN-∝2b arm.6 Of the intent to treat population, 35 
patients in the TMZ + IFN-∝2b group demonstrated either complete or partial response, 
compared to 18 patients in the TMZ group.6 Partial or complete response was defined as 
remission or >50% decrease in disease bulk as measured by physical exam, CT, or MRI.6 These 
measurements were performed before treatment and after every second cycle. Of these 
individuals who demonstrated either partial or complete response, 17 of 35 patients in the TMZ + 
IFN-∝2b group (48.6%) survived longer than 12 months, compared to TMZ alone where 7 of 18 
patients (38.9%) survived longer than 12 months.6 This translated to a relative benefit increase 
(RBI) of 24.9%, an absolute benefit increase of 9.7%, and a number needed to treat (NNT) of 
11(Table 2). No statistical tests were performed on this data. 
Danson et al measured one-year survival rates out of the total intent to treat population.5 
Of those who received TMZ alone, 18% were alive at 12 months, compared to 26% of the group 
who received TMZ + IFN-∝2b.5 This translated to a RBI of 44.4%, an ABI of 8%, and an NNT 
of 13 (Table 2). No statistical tests were performed on this data.  
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Table 2. Survival greater than or equal to 12 months 
Study TMZ alone TMZ + IFN-
A2B 
Relative 
benefit 
increase 
(RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number 
needed to treat 
(NNT) 
Kaufman et 
al 
38.9% 48.6% 24.9% 9.7% 11 
Danson et al 18% 26% 44.4% 8% 13 
 
 Ritchtig et al noted the number of patients who experienced adverse drug events. For this 
study it is important to differentiate adverse drug events, in which a patient is harmed by the 
drug, from common side effects such as nausea, vomiting, arthralgia, and fatigue. Of the group 
that received TMZ + IFN-∝2b in a BSA-based dose (control), 2 out of 20 experienced adverse 
drug events, which included sepsis and brain hemorrhage.7 Of the group that received TMZ + 
IFN-∝2b in a fixed dose (experimental), three out of 27 experienced adverse drug events, which 
included two patients with neurological symptoms and one with a drug-induced skin eruption.7 
Ritchtig et al does not indicate the severity nor the outcome of these events, nor does he perform 
statistical tests to indicate if any significant difference was observed between the two groups. 
These data translate to a relative risk increase (RRI) of 11.1% of a fixed versus weight-based 
dose, an absolute risk increase (ARI) of 1.1%, and a number needed to harm (NNH) of 90 (Table 
3). Referencing the dosages of each group from Table 1, it should be noted that the fixed dose of 
IFN-∝2b for the experimental group of 10 mIU is far lower than the weight-based dose of the 
control of 10 MIU/m2. Therefore the lower dosage of the control group is associated with fewer 
adverse events.  
 The most common side effect reported in Danson et al was nausea.5 Nausea, in part, 
represents the toxicity that the drug treatment regimen had on the patients, and is important to 
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take note of because it influences the quality of life of these critical patients. In the group that 
received TMZ alone, 39% experienced nausea, compared to 49% of those who received TMZ + 
IFN-∝2b.5 This correlates with a RRI of 28.5%, ARI of 11%, and a NNH of 10 (Table 3).  
Table 3. Adverse drug events and side effects 
Outcome Control 
event rate 
Experimental 
event rate 
Relative risk 
increase 
(RRI) 
Absolute 
risk 
increase 
(ARI) 
Number 
needed to 
harm (NNH) 
Adverse 
drug events 
0.10 0.111 11.1% 1.1% 90 
Nausea 0.39 0.49 28.9% 11% 10 
 
DISCUSSION 
 Based on the results for survival at or greater than 12 months from Kaufman et al and 
Danson et al (Table 2), one can see a modest increased benefit in the combination treatment of 
TMZ and IFN-∝2b as opposed to using TMZ alone. Neither of the studies performed statistical 
analyses on this particular data and therefore it is unknown if these findings are statistically 
significant.  
Analyzing the calculated NNT is perhaps the best way for both patients and academics 
alike to appreciate the true benefit, or lack thereof, of the treatment of interest. The results from 
Kaufman et al and Danson et al showed a NNT of 11 and 13, respectively, meaning that for 
every 11-13 patients treated with the regimen of interest, one patient would benefit in the form of 
surviving greater than or equal to 12 months. Although the NNT are relatively low, it is more 
accurate to interpret the data in the context of the quality of the life that the addition of IFN-∝2b 
is adding for these patients. The patients participating in these studies have stage IV melanoma, 
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which historically has been resistant to chemotherapy, and carries about a 10% survival rate.4 
The poor survival rate highlights the importance of considering the adverse effects that these 
drugs have in the interest of quality of life. 
The rate of adverse events studied by Ritchtig et al resulted in a NNH of 90 (Table 3). A 
high NNH translates to a low risk of harm, however, this number in this context is misleading for 
two reasons. For one, the severity of the adverse events varies greatly. These events ranged from 
sepsis and brain hemorrhage in the control group to neurological symptoms and drug-induced 
skin eruption in the experimental group. The outcomes of these adverse events are not discussed. 
Secondly, this measurement has a very small sample size of 47 patients total. The combination of 
the wide range of adverse events and the small sample size makes it difficult to ascertain from 
this data whether the addition of IFN-∝2b to TMZ is safe in the treatment of stage IV melanoma.  
Danson et al observed an ARI in nausea of 11% with the addition of IFN-∝2b to TMZ 
treatment. Statistical tests were not performed on the data, however with a NNH of 10 (Table 3), 
one can ascertain that the combination treatment is associated with an increased risk of nausea. 
This plays a role in the quality of life of the patients and should be taken into consideration when 
choosing treatment options. 
All of the studies included had limitations that should be discussed. For one, none of the 
trials were blinded, which allows the potential for bias to be introduced into the study. 
Additionally, Ritchtig et al had a relatively small sample size, with 20 patients in his control 
group and 27 in the experimental.7 Kaufman et al excluded patients that had metastases to the 
central nervous system,6 however one of the advantages of using TMZ over dacarbazine is that it 
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is able to penetrate the blood-brain barrier,5 and therefore perhaps its full effects were not 
observed.  
TMZ is an oral drug that is nonenzymatically converted into its active form and is able to 
penetrate the blood-brain barrier.5 It exerts its effects by DNA alkylation, which leads to breaks 
in the DNA strands and apoptosis.8 It is widely used in the Unites States as an antineoplastic 
agent for conditions such as glioblastoma multiforme, cutaneous T-cell lymphoma, melanoma, 
Ewing sarcoma, and anaplastic astrocytoma.8 Warnings exist for its potential to cause 
myelosuppression, nausea and emesis, hepatotoxicity, Pneumocystis jirovercii pneumonia, and 
rarely, secondary malignancies.8 
IFN-∝2b is commonly used as an antineoplastic agent, biological response modulator, or 
immunomodulator for conditions such as hairy cell leukemia, lymphoma, melanoma, Kaposi 
sarcoma, chronic hepatitis B and C, and condyloma acuminata.9 U.S. Boxed Warnings exist due 
to its potential to cause or aggravate neuropsychiatric disorders, autoimmune disease, infectious 
disorders, and ischemic disorders.9 The wide range of adverse effects that is associated with IFN-
∝2b may potentially limit its use. 
CONCLUSION 
It is difficult to definitively conclude whether the benefits of treatment with TMZ + IFN-
∝2b outweigh the risks. Although the combination treatment in both Kaufman et al and Danson 
et al yielded improved survival, no statistical tests were performed on these results in order to 
determine if there was a significant difference between groups.5,6 The studies also demonstrated 
increased rates of adverse effects with combination treatment, but of unknown statistical 
significance. Therefore further research should be aimed at determining the statistical 
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significance of survival outcomes and rates of adverse effects in combination treatment of TMZ 
and IFN-∝2b versus TMZ alone. Additionally, since a major advantage of TMZ over 
dacarbazine, which is the current standard chemotherapy, is its ability to penetrate the blood-
brain barrier,5 further study should be aimed toward the effect of TMZ on patients with brain 
metastases. This is particularly important due to the propensity of melanoma to metastasize to 
the brain. The addition of more research, however, will not replace the importance of the 
personal choice to undergo intensive treatment, but it will hopefully help guide families to make 
the most educated decision possible.  
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